Scancell Share Discussion Threads

[marcusl2] 03/1/2022 09:21

Abstract
SARS-CoV-2 variants have become a major virological, epidemiological and clinical concern, particularly with regard to the risk of escape from vaccine-induced immunity. Here we describe the emergence of a new variant. For twelve SARS-CoV-positive patients living in the same geographical area of southeastern France, qPCR testing that screen for variant-associated mutations showed an atypical combination. The index case returned from a travel in Cameroon. The genomes were obtained by next-generation sequencing with Oxford Nanopore Technologies on GridION instruments within approximately 8 h. Their analysis revealed 46 mutations and 37 deletions resulting in 30 amino acid substitutions and 12 deletions. Fourteen amino acid substitutions, including N501Y and E484K, and 9 deletions are located in the spike protein. This genotype pattern led to create a new Pangolin lineage named B.1.640.2, which is a phylogenetic sister group to the old B.1.640 lineage renamed B.1.640.1. Both lineages differ by 25 nucleotide substitutions and 33 deletions. The mutation set and phylogenetic position of the genomes obtained here indicate based on our previous definition a new variant we named 'IHU'. These data are another example of the unpredictability of the emergence of SARS-CoV-2 variants, and of their introduction in a given geographical area from abroad.

[marcusl2] 02/1/2022 15:14

Yes same from me amigo. Hopefully this will be a great year for investors and patients.

[torquayfan] 02/1/2022 14:45

Thanks Marcus and a Happy New Year to you and all.

[wanderer1210_0] 02/1/2022 13:02

"As many people are afraid of needles" Over 133 million covid "vaccinations" given in UK suggest this is not correct.

[marcusl2] 02/1/2022 12:11

What about three times ;-)

[888icb] 02/1/2022 01:31

Tipped in the Guardian yesterday
Scancell
This spinout from the University of Nottingham, founded in 1997 by Lindy Durrant, professor of cancer immunotherapy at the university, specialises in developing cancer vaccines and has started testing them on humans. But when the pandemic struck, the company decided to modify its vaccine technology to develop Covid shots, in collaboration with Nottingham’s two universities and backed by £2m funding from the UK’s innovation agency.

The vaccines aim to induce high T-cell immune responses in the body to identify and kill infected cells, as well as generating virus-neutralising antibodies. Scientists say a strong T-cell response would offer longer-lasting immunity, because the protection from antibodies wanes more quickly, as the current Covid jabs show.

As many people are afraid of needles, Scancell decided its vaccines would be administered via spring-powered injectors that use a narrow stream of fluid to pierce the skin. The first trials with 40 healthy volunteers started in South Africa in October, and a further trial is planned in the UK, and data from the studies is expected by June.

The company’s two main shareholders are the US health investor Redmile and the Singaporean Vulpes Life Science Fund, while Durrant and other management own 1.8% of the company. Its shares have rocketed in the past two years, from nearly 7p in early January 2020 to over 20p, but remain far below their closing high of nearly 57p, reached in October 2012.
Julia Kollewe

[dominiccummings] 01/1/2022 19:25

Oops.... still, worth saying twice!

[dominiccummings] 01/1/2022 19:24

Recommendation in Guardian

Scancell
This spinout from the University of Nottingham, founded in 1997 by Lindy Durrant, professor of cancer immunotherapy at the university, specialises in developing cancer vaccines and has started testing them on humans. But when the pandemic struck, the company decided to modify its vaccine technology to develop Covid shots, in collaboration with Nottingham’s two universities and backed by £2m funding from the UK’s innovation agency.

The vaccines aim to induce high T-cell immune responses in the body to identify and kill infected cells, as well as generating virus-neutralising antibodies. Scientists say a strong T-cell response would offer longer-lasting immunity, because the protection from antibodies wanes more quickly, as the current Covid jabs show.

As many people are afraid of needles, Scancell decided its vaccines would be administered via spring-powered injectors that use a narrow stream of fluid to pierce the skin. The first trials with 40 healthy volunteers started in South Africa in October, and a further trial is planned in the UK, and data from the studies is expected by June.

The company’s two main shareholders are the US health investor Redmile and the Singaporean Vulpes Life Science Fund, while Durrant and other management own 1.8% of the company. Its shares have rocketed in the past two years, from nearly 7p in early January 2020 to over 20p, but remain far below their closing high of nearly 57p, reached in October 2012.

[bermudashorts] 01/1/2022 18:16

Thanks for the heads up Masurenguy

[masurenguy] 01/1/2022 17:50

Tipped in The Guardian today. I have no position here yet.

Spinout from the University of Nottingham, specialises in developing cancer vaccines and has started testing them on humans. When the pandemic struck, the company decided to modify its vaccine technology to develop Covid shots to induce high T-cell immune responses in the body to identify and kill infected cells, as well as generating virus-neutralising antibodies. Scientists say a strong T-cell response would offer longer-lasting immunity, because the protection from antibodies wanes more quickly, as current Covid jabs show. The company’s 2 main shareholders are the US health investor Redmile and the Singaporean Vulpes Life Science Fund, while Professor Durrant and other management own 1.8% of the company. Its shares have rocketed in the past 2 years, from nearly 7p in early January 2020 to over 20p, but remain far below their closing high of nearly 57p, reached in 2012.

[marcusl2] 01/1/2022 15:34

“We have the electroporation devices from people like I-Core and Inovio and now we also have the needle-free injection devices from people like Pharmajet, which is what Zydus Cadila uses,” said Horton. “These ways of basically helping DNA to get into cells have made the difference between an immunogenic, and non-immunogenic DNA vaccine.”

DNA vaccines come with other benefits. In trials so far, they appear to be very safe. “We haven’t really seen safety concerns,” says Horton. “Whereas with the other platforms that are out there—luckily the side effects are rare—but there are some safety issues with both the mRNA and the viral vector vaccines.”

DNA vaccines are also highly stable and do not need the kind of expensive, low temperature storage the two mRNA vaccines require, likely something that factored into Zydus’s decision to develop a DNA vaccine for the Indian population

Another advantage to DNA vaccines is the kind of immune response they produce from the body. The available mRNA vaccines for COVID-19 produce strong antibody and CD4 T cell responses, but not much in the way of CD8 T cell response. Conversely, the viral vector vaccines produce strong CD8 responses, but less in the way of other immune cells.

“DNA vaccines are able to generate both antibody and T cell responses,” said Broderick, which includes both CD8 and CD4 responses, confirmed Horton. The Zydus Cadila vaccine had moderate 67% efficacy at protecting against symptomatic disease in clinical trials, but this broader immune response may mean the protection it offers lasts for longer (although this has yet to be confirmed).

“It’s probably why DNA vaccines have actually performed quite well in cancer,” says Horton, “there are a number of vaccines that are now in quite late stage trials for cancer that are DNA vaccines.”

[ivyspivey] 31/12/2021 21:57

Evening All.
Goosed just taking a little time out from a quiet New Year at home to have a little catch up.
Think you captured many of the sentiments felt on here and I find it sad that many issues now seem to totally divide society and rather than try and work together to make things better which after the awful suffering endured by many due the Pandemic you think we would all want some seem more interested in just peddling their views.
I do wish everyone a very happy New Year and even though there imo some great positives like the response of the Scientific community and the way the NHS and others have really worked incredibly hard there have been negatives as well.
Rather than make judgments on who got what right regarding very difficult decisions I truly hope in 2022 we can put most of this division behind us,return to some form of normality and seek to make the world a better place to live.

[bountyhunter] 31/12/2021 20:00

On my watch list.

[emptyend] 31/12/2021 17:46

Panama is just a deranged nutter. But you are entirely right that he is safer here than addressing anyone who might listen to him for a nanosecond...Happy New Year to all.....hopefully the government will devise a future-proofed vaccine strategy that Scancell will be part of...

[panama7] 31/12/2021 14:28

TF, where are you spending it , hiding behind your settee, double masked and triple jabbed no doubt.

[panama7] 31/12/2021 14:20

Gecko, Paul Hunter states that the daily count of cases will not be warranted in the future. They haven't been warranted for over 18 months but they still churn them out. As that evil imbecile empty Vessel states the Government had to keep up the ratchet of military grade fear and propaganda to get the population to be part of the biggest medical experiment carried out on mankind. What a truly evil, despicable human being.

[torquayfan] 31/12/2021 14:18

Happy New Year everybody - that's even for P7 !
Only 3 hours away right here now - 2022 can't be worse than the present can it ?

ATB all and HNY even Banan . . .

[emptyend] 30/12/2021 11:40

Hunter has spoken good sense throughout. Though vulnerable populations (eg 65+) will continue to be vaccinated and the need for better vaccines will persist.